Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

Losina E, Yazdanpanah Y, Deuffic-Burban S, Wang B, Wolf LL, Messou E, Gabillard D, Seyler C, Freedberg KA, Anglaret X.

Antivir Ther. 2007;12(4):543-51.

2.

Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire.

Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR 3rd, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie SJ, Messou E, Weinstein MC, Deuffic-Burban S, Salamon R, Freedberg KA.

S Afr Med J. 2006 Jun;96(6):526-9.

3.

Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.

Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, Divi N, Freedberg KA, Anglaret X, Yazdanpanah Y.

Eur J Epidemiol. 2007;22(10):737-44. Epub 2007 Sep 8.

4.

Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire.

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, Gomis OB, Konga C, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X.

Antivir Ther. 2005;10(5):615-24.

PMID:
16152755
5.

AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.

Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M, Coulibaly A, Freedberg KA, Lewden C, Ménan H, Abo Y, Dakoury-Dogbo N, Toure S, Seyler C; ANRS 12222 Morbidity/Mortality Study Group.

Clin Infect Dis. 2012 Mar 1;54(5):714-23. doi: 10.1093/cid/cir898. Epub 2012 Feb 4.

6.

Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study.

Harouna AM, Amorissani-Folquet M, Eboua FT, Desmonde S, N'Gbeche S, Aka EA, Kouadio K, Kouacou B, Malateste K, Bosse-Amani C, Ahuatchi Coffie P, Leroy V; IeDEA paediatric West African Study Group.

BMC Infect Dis. 2015 Aug 7;15:317. doi: 10.1186/s12879-015-1009-6.

7.

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.

Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, Manlan K, N'Dri-Yoman T, Salamon R.

Lancet. 1999 May 1;353(9163):1463-8.

PMID:
10232311
8.

Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.

Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X.

Am J Respir Crit Care Med. 2005 Jul 1;172(1):123-7. Epub 2005 Apr 1.

PMID:
15805184
9.

CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.

Danel C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu G, Gabillard D, Rouet F, Sorho S, Chaix ML, Eholié S, Menan H, Sauvageot D, Bissagnene E, Salamon R, Anglaret X; Trivacan ANRS 1269 trial group.

Lancet. 2006 Jun 17;367(9527):1981-9.

PMID:
16782488
10.

Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.

Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Touré S, Danel C, Diakité N, Daudié A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

Antivir Ther. 2003 Oct;8(5):385-93.

PMID:
14640385
11.

Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.

Diabaté S, Alary M.

HIV Med. 2009 Nov;10(10):640-6. doi: 10.1111/j.1468-1293.2009.00736.x. Epub 2009 Jul 29.

12.

Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.

Kasirye R, Grosskurth H, Munderi P, Levin J, Anywaine Z, Nunn A, Kamali A, Baisley K.

Malar J. 2016 Jul 15;15:361. doi: 10.1186/s12936-016-1426-z.

13.

Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire.

Minga A, Danel C, Abo Y, Dohoun L, Bonard D, Coulibaly A, Duvignac J, Dabis F, Salamon R, Anglaret X; ANRS 1220 Study Group.

Bull World Health Organ. 2007 Feb;85(2):116-23.

14.

Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Côte d'Ivoire.

Anglaret X, Messou E, Ouassa T, Toure S, Dakoury-Dogbo N, Combe P, Mahassadi A, Seyler C, N'Dri-Yoman T, Salamon R; ANRS 1203 Study Group.

AIDS. 2003 Mar 7;17(4):575-84.

PMID:
12598778
15.

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.

Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A, Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock KM, Coulibaly IM, Greenberg AE.

Lancet. 1999 May 1;353(9163):1469-75. Erratum in: Lancet 1999 Jun 12;353(9169):2078.

PMID:
10232312
16.

Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults.

Miiro G, Todd J, Mpendo J, Watera C, Munderi P, Nakubulwa S, Kaddu I, Rutebarika D, Grosskurth H.

Trop Med Int Health. 2009 May;14(5):556-63. doi: 10.1111/j.1365-3156.2009.02259.x. Epub 2009 Mar 19.

17.

Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.

Walenda C, Kouakoussui A, Rouet F, Wemin L, Anaky MF, Msellati P.

J Trop Pediatr. 2009 Jun;55(3):170-6. doi: 10.1093/tropej/fmn106. Epub 2008 Dec 9.

PMID:
19066169
18.

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.

Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA.

N Engl J Med. 2006 Sep 14;355(11):1141-53.

19.

High incidence of atypical mycobacteriosis in African HIV-infected adults with low CD4 cell counts: a 6-year cohort study in Côte d'Ivoire.

Bonard D, Messou E, Seyler C, Vincent V, Gabillard D, Anglaret X.

AIDS. 2004 Sep 24;18(14):1961-4.

PMID:
15353985
20.

18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Côte d'Ivoire: a cohort study.

Harambat J, Fassinou P, Becquet R, Touré P, Rouet F, Dabis F, Msellati P, Blanche S, Timité-Konan M, Salamon R, Leroy V; ANRS 1201/1202 Ditrame Plus Study Group.

BMC Public Health. 2008 May 20;8:169. doi: 10.1186/1471-2458-8-169.

Supplemental Content

Support Center